Research Topics
| P D SenterSummaryAffiliation: Seattle Genetics Country: USA Publications
| Collaborators
|
Detail Information
Publications
Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugsBrian E Toki
Seattle Genetics, 21823 30th Drive SE, Bothell, Washington 98021, USA
J Org Chem 67:1866-72. 2002..This result extends the use of the self-immolative p-aminobenzyl group for the fragmentation of aromatic ethers and provides a new strategy for anticancer prodrug development...
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphomaPeter D Senter
Seattle Genetics, Bothell, Washington, USA
Nat Biotechnol 30:631-7. 2012..Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies...- Potent antibody drug conjugates for cancer therapyPeter D Senter
Seattle Genetics, Inc, 21823 30th Dr SE, Bothell, WA 98021, United States
Curr Opin Chem Biol 13:235-44. 2009..This review details many of the technological advancements, and provides examples of promising ADCs that are currently in clinical trials... - Drug carriers in medicine and biologyPeter D Senter
Seattle Genetics, Bothell, Washington 98021, USA
Mol Pharm 1:395-8. 2004 - Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drugP D Senter
Seattle Genetics, Inc 21823 30th Drive SE, Bothell, Washington 98021, USA
Bioconjug Chem 12:1074-80. 2001..These results confirm the importance of hCE-2 for CPT-11 activation and underscore the importance of enzyme kinetics for selective prodrug activation... - Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugatesP D Senter
Seattle Genetics, 21823 30th Dr SE, Bothell, WA 98021, USA
Adv Drug Deliv Rev 53:247-64. 2001.... - Dipeptide-based highly potent doxorubicin antibody conjugatesScott C Jeffrey
Department of Chemistry, Seattle Genetics, 21823 30th Drive SE, Bothell, WA 98021, USA
Bioorg Med Chem Lett 16:358-62. 2006..The approaches described here for attaching highly potent doxorubicin derivatives to mAbs are novel and allow for control of drug stability while covalently bound to the delivery agent... - Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicitySvetlana O Doronina
Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
Bioconjug Chem 17:114-24. 2006..Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indices... - Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugatesMay S Kung Sutherland
Department of Molecular Oncology and Immunology, Seattle Genetics Inc, 21823-30th Drive SE, Bothell, WA 98021, USA
J Biol Chem 281:10540-7. 2006.... - Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugatesChe Leung Law
Seattle Genetics, Inc, Bothell, Washington 98021, USA
Cancer Res 66:2328-37. 2006.... - CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanomaKam Fai Tse
CuraGen, Branford, Connecticut 06405, USA
Clin Cancer Res 12:1373-82. 2006..25 mg/kg. CONCLUSION: These preclinical results support the continued evaluation of CR011-vcMMAE for the treatment of melanoma... - Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)Ralph F Alderson
Genencor International, a Danisco company, 925 Page Mill Road, Palo Alto, California 94304, USA
Bioconjug Chem 17:410-8. 2006..5, in combination with a novel prodrug, GC-Mel, resulted in significant efficacy in a colorectal xenograft tumor model and supports the utility of the protein as an agent for tumor-selective prodrug activation... - Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigenDangshe Ma
PSMA Development Co LLC, Tarrytown, New York, USA
Clin Cancer Res 12:2591-6. 2006..Importantly, 40% of treated animals had no detectable tumor or measurable PSA at day 500 and could be considered cured. The findings support development of PSMA antibody-auristatin conjugates for therapy of prostate cancer... - Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugatesScott C Jeffrey
Seattle Genetics, 21823 30th Drive SE, Bothell, Washington 98021, USA
Bioconjug Chem 17:831-40. 2006..75 mg/kg. These results demonstrate that the beta-glucuronide linker system is an effective strategy for targeting cytotoxic agents providing ADCs with high degrees of efficacy at well-tolerated doses... - Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linkerScott C Jeffrey
Seattle Genetics Inc, 21823 30th Drive S E, Bothell, WA 98021, USA
Bioorg Med Chem Lett 17:2278-80. 2007..The water soluble beta-glucuronide linker is stable in plasma and effectively delivers drugs to target cells leading to potent cytotoxic activities... - Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMBVincent A Pollack
Department of Preclinical Development, CuraGen Corporation, 322 E Main St, Branford, CT 06405, USA
Cancer Chemother Pharmacol 60:423-35. 2007.... - Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivativeKai Temming
Department of Pharmacokinetics and Drug Delivery, University Center for Pharmacy, University of Groningen, Groningen, The Netherlands
Mol Pharm 4:686-94. 2007.... - Contribution of linker stability to the activities of anticancer immunoconjugatesStephen C Alley
Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, WA 98021, USA
Bioconjug Chem 19:759-65. 2008..In summary, the data indicate that new linkers can be obtained with improved in vivo stability by replacing the maleimide with an acetamide, but the resulting ADCs had similar tolerability and activity profiles... - Antibody-drug conjugates for cancer therapyPaul J Carter
Seattle Genetics, Inc, Bothell, Washington 98021, USA
Cancer J 14:154-69. 2008..This review details these advances, discusses some of the remaining challenges, and overviews ADCs currently in clinical trials for cancer therapy... 
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfidesMichael M C Sun
Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
Bioconjug Chem 16:1282-90. 2005..The resulting conjugates are highly active both in vitro and in vivo and are well tolerated at efficacious doses...- Arming antibodies: prospects and challenges for immunoconjugatesAnna M Wu
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Box 951770, 700 Westwood Plaza, Los Angeles, California 90095, USA
Nat Biotechnol 23:1137-46. 2005..Nonetheless, highly promising results from preclinical models will continue to drive the clinical development of this therapeutic class... - Reductively activated disulfide prodrugs of paclitaxelVivekananda M Vrudhula
Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Bioorg Med Chem Lett 12:3591-4. 2002..These compounds behaved as prodrugs in vitro on L2987 lung carcinoma cells. In vivo evaluation in mice demonstrated that the mutual prodrug 5 with captopril exhibited significant regressions and cures... - Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion proteinVivekananda M Vrudhula
Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
Bioorg Med Chem Lett 13:539-42. 2003..Immunologically specific activation of the prodrug 5 containing 3,3-dimethyl-4-amino-butyric acid as linker in combination with the fusion protein L-49-sFv-beta-lactamase was demonstrated in vitro on 3677 melanoma cells... - cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activityJoseph A Francisco
Seattle Genetics, Bothell, WA 98021, USA
Blood 102:1458-65. 2003..Mice treated at 30 mg/kg cAC10-vcMMAE showed no signs of toxicity. These data indicate that cAC10-vcMMAE may be a highly effective and selective therapy for the treatment of CD30+ neoplasias... - Development of potent monoclonal antibody auristatin conjugates for cancer therapySvetlana O Doronina
Seattle Genetics, Inc, 21823 30th Dr. SE, Bothell, Washington 98021, USA
Nat Biotechnol 21:778-84. 2003..These conjugates illustrate the importance of linker technology, drug potency and conjugation methodology in developing safe and efficacious mAb-drug conjugates for cancer therapy... - Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineeringCharlotte F McDonagh
Seattle Genetics Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
Bioconjug Chem 14:860-9. 2003..These results show that a rational protein-engineering approach improved the yield, stability, and refolding characteristics of L49-sFv-bL while maintaining binding affinity and therapeutic efficacy... - Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugatesCraig Beeson
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Bioconjug Chem 14:927-33. 2003..These studies demonstrate that the cleavable RIC substrate is able to bind to tumor antigens and localize within human tumor xenografts and that accelerated systemic clearance can be induced with beta-lactamase... - Efficient cancer therapy with a nanobody-based conjugateVirna Cortez-Retamozo
Department of Molecular and Cellular Interactions, Flanders Interuniversity Institute for Biotechnology, Vrije Universiteit Brussel, Brussels, Belgium
Cancer Res 64:2853-7. 2004..The easy generation and manufacturing yield of nanobody-based conjugates together with their potent antitumor activity make nanobodies promising vehicles for new generation cancer therapeutics... - Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathwayKerry Klussman
Department of Biochemistry, Seattle Genetics, Inc, 21823 - 30th Drive Southeast, Bothell, Washington 98021, USA
Bioconjug Chem 15:765-73. 2004..This homogeneous screening system is amenable to medium-throughput screening applications and enables the early identification of mAbs capable of intracellular trafficking for drug delivery and release... - Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugateKevin J Hamblett
Seattle Genetics, Inc, Bothell, Washington 98021, USA
Clin Cancer Res 10:7063-70. 2004..CONCLUSIONS: By decreasing drug loading per antibody, the therapeutic index was increased demonstrating that drug loading is a key design parameter for antibody-drug conjugates... - Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugatesChe-Leung Law
Seattle Genetics, Inc, 21823-30th Drive Southeast, Bothell, WA 98021, USA
Clin Cancer Res 10:7842-51. 2004..These data indicate that anti-CD20-based antibody-drug conjugates are effective antitumor agents when prepared with a stable, enzyme-cleavable peptide linkage to highly potent cytotoxic agents such as MMAE... - In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugateRussell J Sanderson
Seattle Genetics Inc, 21813 30th Drive Southeast, Bothell, WA 98021, USA
Clin Cancer Res 11:843-52. 2005..These data represent the longest reported drug-linker half-life to date and provide the basis for the pronounced specificity and antitumor activity of cAC10-valine-citrulline-MMAE... - Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugatesScott C Jeffrey
Seattle Genetics, 21823 30th Drive SE, Bothell, WA 98021, USA
J Med Chem 48:1344-58. 2005..The results provide a general strategy for MGB prodrug design and illustrate the importance of linker hydrophilicity in making nonaggregated, active mAb-MGB conjugates... - Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9Toni Kline
Seattle Genetics, Bothell, Washington 98021, USA
Mol Pharm 1:9-22. 2004..Our data can be interpreted in light of the current understanding of the structural and mechanistic factors governing MMP-2 and -9 proteolysis... - Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugateMichael Y Torgov
Seattle Genetics, 21823 30th Drive SE, Bothell, Washington 98021, USA
Bioconjug Chem 16:717-21. 2005..The potential of this enzyme/prodrug combination for cancer therapy is discussed... - Chemotherapy delivery issues in central nervous system malignancy: a reality checkLeslie L Muldoon
Department of Neurology, Oregon Health and Science University, Portland, and the Veterans Administration Medical Center, OR 97239 3098, USA
J Clin Oncol 25:2295-305. 2007..This review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006... - Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activityAngeles Dios
The Picower Institute for Medical Research, Manhasset, NY 11030, USA
J Med Chem 45:2410-6. 2002..The inhibitory activity of amino acid-benzaldehyde Schiff base-type MIF antagonists is the first step toward a meaningful structure/function analysis of inhibitors of MIF cellular bioactivities...